Two Deaths Potentially Linked to Weight-Loss Jabs Reported to UK Drug Watchdog
The UK's Medicine and Healthcare Regulatory Agency (MHRA) has received reports concerning the deaths of a man and a woman in Northern Ireland, with fears they may be connected to popular weight-loss medications. These fatalities, reported in 2024 and 2025, were part of more than 500 adverse drug reaction submissions from Northern Ireland during that period, all suspected to be tied to GLP-1 drugs like Mounjaro, Wegovy, and Ozempic.
Regulatory Response and Safety Monitoring
Dr Alison Cave, the chief safety officer of the MHRA, emphasised that patient safety remains the agency's top priority. "No medicine would be approved unless it met our expected standards of safety, quality and effectiveness," she stated. The MHRA maintains robust safety monitoring systems, including the Yellow Card scheme, which allows healthcare professionals and the public to report suspected side effects. It is crucial to note that a report does not confirm the drugs caused the deaths or adverse reactions, but indicates a suspicion by the reporter.
Dr Cave added, "When a safety issue is confirmed, we always act promptly to inform patients and healthcare professionals and take appropriate steps to mitigate any identified risk." The agency continues to encourage reporting through the Yellow Card Scheme to enhance surveillance.
Rising Usage and Specific Incident Details
Britain has experienced a sharp increase in the use of GLP-1 medications, which are also prescribed for diabetes treatment. According to University College London, approximately 1.6 million adults in the UK used weight-loss drugs between early 2024 and early 2025. Of the two deaths reported to the MHRA, one was linked to Mounjaro, while the other involved an unspecified semaglutide, the active ingredient in many weight-loss jabs. The deceased individuals were in their 40s and 60s, though the report did not specify which age applied to each person.
Breakdown of Adverse Reaction Reports
Data from January 2024 to December 2025 revealed detailed insights into the adverse reactions reported:
- Out of over 500 reports from Northern Ireland, 419 (82%) were submitted by healthcare professionals.
- An additional 92 reports came from patients, parents, and carers.
- Specifically, 317 suspected reactions were tied to Mounjaro, and 135 were linked to Wegovy.
- Among all incidents reported to the MHRA, 242 were classified as "serious," while 267 were deemed "non-serious."
- Notably, one serious report involved a child under 10 years old, though the medication was not specified.
Balancing Benefits and Risks
Despite these reports, the MHRA asserts that the benefits of GLP-1 medicines generally outweigh the potential risks when used for licensed indications. Dr Cave advised, "The decision to start, continue or stop treatments should be made jointly by patients and their doctor, based on full consideration of the benefits and risks." This underscores the importance of informed medical guidance in the use of these medications.
The ongoing monitoring and reporting efforts aim to ensure that any emerging safety concerns are addressed swiftly, maintaining public trust in pharmaceutical regulations and healthcare practices.
